Following the expanded approval, the accelerated approval for the later-line CLL/SLL was converted to a traditional approval.

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...